Disease-free survival and cumulative incidence of relapse according to treatment protocol and relapse risk group. (A) Kaplan-Meier product-limit estimate of disease-free survival (DFS) and cumulative incidence of relapse (CIR) according to whether they received anthracycline monochemotherapy consolidation (LPA96 study) or risk-adapted consolidation (LPA99 study). (B) CIR of patients in the LPA99 trial according to the relapse risk group.